• Patrys crosses blood brain barrier in health animals
  • Cynata receives Notice of Acceptance from IP Australia
  • Telix announces collaboration with GE Healthcare

Patrys (ASX:PAB) surged 15% this morning after announcing that its full-sized deoxymab antibody, PAT-DX3, has crossed the blood brain barrier in healthy animals.

The study found that the uptake into the brain (per cubic centimetre) of PAT-DX3 was 3–4 fold higher than that of a control antibody soon after injection, and this persisted for the duration of the study period.

This compares favourably to antibodies that have been specifically engineered for enhanced blood-brain barrier crossing that have reported brain uptake values of just 2–3 fold higher.

The blood-brain barrier acts as an additional boundary between the circulating blood and the extracellular space of the brain.

The barrier is highly selective, meaning it only allows certain substances to cross from the bloodstream into the brain.

The ability of PAT-DX3 to cross the blood-brain barrier is consistent with current data which indicates that Patrys’ deoxymabs enter cells using the ENT2 transporter protein; a protein which is highly expressed in the neural vasculature.

“This is an important result that opens up a range of potential applications for Patrys and its development partners,” said Patrys CEO, Dr James Campbell.

Graham explained that unlike deoxymabs, none of the other antibodies are able to deliver their payloads into the cell and the cell nucleus.

“PAT-DX3 appears to out-perform antibodies specifically developed by other companies for the delivery of payloads to brain tissue.”

“As we advance PAT-DX1 towards the first clinical trial in cancer patients in H2 CY23, it is very exciting for Patrys to be able to identify additional applications for PAT-DX3 that may open up new development or partnering opportunities for the company,” Graham said.


Patrys share price today:


IP Australia accepts Cynata’s patent application

Cynata Therapeutics (ASX:CYP) announced that a Notice of Acceptance has been received from IP Australia for a patent application, entitled “Colony Forming Medium and Use Thereof”.

This patent application covers its proprietary Cymerus mesenchymal stem cell (MSC) technology.

In short, MSC therapies work by expressing a variety of chemokines and cytokines that aid in repair of degraded tissue, and counteract inflammation.

Because MSCs play a co-ordination role within the immune system, they can be used to treat different diseases.

Telix signs deal with GE Healthcare

Telix Pharma (ASX:TLX) announced a collaborative development and reseller agreement with GE Healthcare to supply its investigational positron emission tomography (PET) imaging radiotracers.

Telix’s TLX250-CDx and [F]-FLac radiotracers offer the potential to provide key information about the metabolic environment of tumours, which could help to inform and improve therapy selection.

The partnership with GE will see Telix’s investigational imaging agents used more widely in third-party clinical trials.


NTI and Argenica give clinical trial updates

Neurotech (ASX:NTI) has launched a new Phase I/II Clinical Trial of NTI164 in PANDAS/PANS.

PANDAS/PANS is a clinical diagnosis given to children who have a dramatic (typically within one day) onset of neuropsychiatric symptoms including intense anxiety, Obsessive-Compulsive Disorder (OCD) and/or severely restrictive eating.

There are currently no US FDA and European Medicines Agency (EMA) approved therapies for PANDAS/PANS and very limited clinical trials of new therapeutic interventions.

NTI164 has previously been proven to be a potent anti-inflammatory and neuro-protective effects in vitro, along with an excellent safety and tolerability profile in paediatric patients with Autism Spectrum Disorder.

Argenica Therapeutics (ASX:AGN) meanwhile announced last week that the first subject was dosed in its Phase 1 clinical trial of ARG-007 in healthy volunteers.

The company said that the first dosed subject has shown no serious safety issues 24 hours after dosing, and therefore dosing of the remaining participants in cohort one will be completed over the next three days.

Following the dosing of these participants, all follow up data will be presented to the Scientific Review Committee who will then confirm the progress of the trial to the next cohort.


Share prices today: